{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:34:41Z","timestamp":1776483281920,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the high costs, the strategy to reduce the impact of cytomegalovirus (CMV) after kidney transplant (KT) involves preemptive treatment in low and middle-income countries. Thus, this retrospective cohort study compared the performance of antigenemia transitioned to quantitative nucleic acid amplification testing, RT-PCR, in CMV-seropositive KT recipients receiving preemptive treatment as a strategy to prevent CMV infection. Between 2016 and 2018, 363 patients were enrolled and received preemptive treatment based on antigenemia (n\u2009=\u2009177) or RT-PCR (n\u2009=\u2009186). The primary outcome was CMV disease. Secondarily, the CMV-related events were composed of CMV-infection and disease, which occurred first. There were no differences in 1-year cumulative incidence of CMV-disease (23.7% vs. 19.1%, p\u2009=\u20090.41), CMV-related events (50.8% vs. 44.1%, p\u2009=\u20090.20), neither in time to diagnosis (47.0 vs. 47.0\u00a0days) among patients conducted by antigenemia vs. RT-PCR, respectively. The length of CMV first treatment was longer with RT-PCR (20.0 vs. 27.5\u00a0days, p\u2009&lt;\u20090.001), while the rate of retreatment was not different (14.7% vs. 11.8%, p\u2009=\u20090.48). In the Cox regression, acute rejection within 30\u00a0days was associated with an increased the risk (HR\u2009=\u20092.34; 95% CI\u2009=\u20091.12\u20134.89; p\u2009=\u20090.024), while each increase of 1\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> of 30-day eGFR was associated with a 2% reduction risk of CMV-disease (HR\u2009=\u20090.98; 95% CI\u2009=\u20090.97\u20130.99; p\u2009=\u20090.001). In conclusion, acute rejection and glomerular filtration rate are risk factors for CMV disease, showing comparable performance in the impact of CMV-related events between antigenemia and RT-PCR for preemptive treatment.<\/jats:p>","DOI":"10.1038\/s41598-022-16847-3","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T08:48:43Z","timestamp":1659170923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection"],"prefix":"10.1038","volume":"12","author":[{"given":"M\u00f4nica Rika","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00facio R.","family":"Requi\u00e3o-Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Mayer","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Botelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Taddeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Almeida","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Rosso","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Medina-Pestana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lio","family":"Tedesco-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"16847_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1681\/ASN.V124848","volume":"12","author":"DC Brennan","year":"2001","unstructured":"Brennan, D. C. Cytomegalovirus in renal transplantation. J. Am. Soc. Nephrol. 12, 848\u2013855. https:\/\/doi.org\/10.1681\/ASN.V124848 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl 3","key":"16847_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","volume":"13","author":"CN Kotton","year":"2013","unstructured":"Kotton, C. N. CMV: Prevention, diagnosis and therapy. Am. J. Transplant. 13(Suppl 3), 24\u201340. https:\/\/doi.org\/10.1111\/ajt.12006 (2013) (quiz 40).","journal-title":"Am. J. Transplant."},{"key":"16847_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","volume":"98","author":"M Stern","year":"2014","unstructured":"Stern, M. et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 98, 1013\u20131018. https:\/\/doi.org\/10.1097\/TP.0000000000000160 (2014).","journal-title":"Transplantation"},{"key":"16847_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton, C. N. et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102, 900\u2013931. https:\/\/doi.org\/10.1097\/TP.0000000000002191 (2018).","journal-title":"Transplantation"},{"key":"16847_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ndt\/gfz268","volume":"35","author":"N Bischof","year":"2020","unstructured":"Bischof, N. et al. Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation. Nephrol. Dial. Transplant. 35, 346\u2013356. https:\/\/doi.org\/10.1093\/ndt\/gfz268 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"16847_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman, P. et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin. Infect. Dis. 64, 87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668 (2017).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 4","key":"16847_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ajt.12103","volume":"13","author":"RR Razonable","year":"2013","unstructured":"Razonable, R. R., Humar, A., Practice, A. I. D. C. o. Cytomegalovirus in solid organ transplantation. Am. J. Transplant. 13(Suppl 4), 93\u2013106. https:\/\/doi.org\/10.1111\/ajt.12103 (2013).","journal-title":"Am. J. Transplant."},{"key":"16847_CR8","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","volume":"6","author":"JA Khoury","year":"2006","unstructured":"Khoury, J. A. et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant. 6, 2134\u20132143. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01413.x (2006).","journal-title":"Am. J. Transplant."},{"key":"16847_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","volume":"8","author":"T Reischig","year":"2008","unstructured":"Reischig, T. et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8, 69\u201377. https:\/\/doi.org\/10.1111\/j.1600-6143.2007.02031.x (2008).","journal-title":"Am. J. Transplant."},{"key":"16847_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3851\/IMP1485","volume":"15","author":"T Reischig","year":"2010","unstructured":"Reischig, T. et al. Intragraft cytomegalovirus infection: A randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Antivir. Ther. 15, 23\u201330. https:\/\/doi.org\/10.3851\/IMP1485 (2010).","journal-title":"Antivir. Ther."},{"key":"16847_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.5935\/0101-2800.20170064","volume":"39","author":"JO Reusing Junior","year":"2017","unstructured":"Reusing Junior, J. O. & David-Neto, E. Cytomegalovirus infection after transplantation: Prevention is still the challenge. J. Bras. Nefrol. 39, 353\u2013354. https:\/\/doi.org\/10.5935\/0101-2800.20170064 (2017).","journal-title":"J. Bras. Nefrol."},{"key":"16847_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcv.2007.12.001","volume":"41","author":"F Baldanti","year":"2008","unstructured":"Baldanti, F., Lilleri, D. & Gerna, G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237\u2013241. https:\/\/doi.org\/10.1016\/j.jcv.2007.12.001 (2008).","journal-title":"J. Clin. Virol."},{"key":"16847_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/01.TP.0000057239.32192.B9","volume":"75","author":"G Gerna","year":"2003","unstructured":"Gerna, G. et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 75, 1012\u20131019. https:\/\/doi.org\/10.1097\/01.TP.0000057239.32192.B9 (2003).","journal-title":"Transplantation"},{"key":"16847_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","volume":"96","author":"CN Kotton","year":"2013","unstructured":"Kotton, C. N. et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96, 333\u2013360. https:\/\/doi.org\/10.1097\/TP.0b013e31829df29d (2013).","journal-title":"Transplantation"},{"key":"16847_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2015.08.010","volume":"225","author":"MA Tremblay","year":"2015","unstructured":"Tremblay, M. A., Rodrigue, M. A., Desch\u00eanes, L., Boivin, G. & Longtin, J. Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. J. Virol. Methods 225, 1\u20133. https:\/\/doi.org\/10.1016\/j.jviromet.2015.08.010 (2015).","journal-title":"J. Virol. Methods"},{"key":"16847_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cid\/cis900","volume":"56","author":"HH Hirsch","year":"2013","unstructured":"Hirsch, H. H. et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin. Infect. Dis. 56, 367\u2013373. https:\/\/doi.org\/10.1093\/cid\/cis900 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"16847_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/cid\/cit096","volume":"56","author":"RR Razonable","year":"2013","unstructured":"Razonable, R. R. et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin. Infect. Dis. 56, 1546\u20131553. https:\/\/doi.org\/10.1093\/cid\/cit096 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"16847_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ctr.12671","volume":"30","author":"MV Dioverti","year":"2016","unstructured":"Dioverti, M. V., Lahr, B. & Razonable, R. R. Treatment of cytomegalovirus infection and disease pre- and post-quantitative nucleic acid test standardization: Does use of a more sensitive assay lead to longer treatment duration?. Clin. Transplant. 30, 154\u2013160. https:\/\/doi.org\/10.1111\/ctr.12671 (2016).","journal-title":"Clin. Transplant."},{"key":"16847_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","volume":"105","author":"S Gliga","year":"2018","unstructured":"Gliga, S. et al. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J. Clin. Virol. 105, 91\u201396. https:\/\/doi.org\/10.1016\/j.jcv.2018.06.009 (2018).","journal-title":"J. Clin. Virol."},{"key":"16847_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","volume":"71","author":"M Jarque","year":"2020","unstructured":"Jarque, M. et al. Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: A prospective, interventional, multicenter clinical trial. Clin. Infect. Dis. 71, 2375\u20132385. https:\/\/doi.org\/10.1093\/cid\/ciz1209 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"16847_CR21","doi-asserted-by":"publisher","first-page":"e13636","DOI":"10.1111\/ctr.13636","volume":"33","author":"MR Jorgenson","year":"2019","unstructured":"Jorgenson, M. R. et al. The risk of cytomegalovirus infection after treatment of acute rejection in renal transplant recipients. Clin. Transplant. 33, e13636. https:\/\/doi.org\/10.1111\/ctr.13636 (2019).","journal-title":"Clin. Transplant."},{"key":"16847_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1399-3062.2010.00533.x","volume":"12","author":"S Bataille","year":"2010","unstructured":"Bataille, S. et al. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl. Infect. Dis. 12, 480\u2013488. https:\/\/doi.org\/10.1111\/j.1399-3062.2010.00533.x (2010).","journal-title":"Transpl. Infect. Dis."},{"key":"16847_CR23","doi-asserted-by":"publisher","first-page":"e13106","DOI":"10.1111\/tid.13106","volume":"21","author":"C Felipe","year":"2019","unstructured":"Felipe, C. et al. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. Transpl. Infect. Dis. 21, e13106. https:\/\/doi.org\/10.1111\/tid.13106 (2019).","journal-title":"Transpl. Infect. Dis."},{"key":"16847_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fimmu.2019.00078","volume":"10","author":"M Clement","year":"2019","unstructured":"Clement, M. & Humphreys, I. R. Cytokine-mediated induction and regulation of tissue damage during cytomegalovirus infection. Front. Immunol. 10, 78. https:\/\/doi.org\/10.3389\/fimmu.2019.00078 (2019).","journal-title":"Front. Immunol."},{"key":"16847_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/TP.0b013e318225dbd0","volume":"92","author":"M Cortinovis","year":"2011","unstructured":"Cortinovis, M., Gotti, E., Pradini, S., Gaspari, F. & Perico, N. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. Transplantation 92, 550\u2013556. https:\/\/doi.org\/10.1097\/TP.0b013e318225dbd0 (2011).","journal-title":"Transplantation"},{"key":"16847_CR26","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/ajt.13327","volume":"15","author":"H Tedesco-Silva","year":"2015","unstructured":"Tedesco-Silva, H. et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am. J. Transplant. 15, 2655\u20132664. https:\/\/doi.org\/10.1111\/ajt.13327 (2015).","journal-title":"Am. J. Transplant."},{"key":"16847_CR27","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1097\/TP.0000000000003124","volume":"104","author":"MI de Paula","year":"2020","unstructured":"de Paula, M. I. et al. The influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis. Transplantation 104, 2139\u20132147. https:\/\/doi.org\/10.1097\/TP.0000000000003124 (2020).","journal-title":"Transplantation"},{"key":"16847_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/tri.13800","volume":"34","author":"MI de Paula","year":"2021","unstructured":"de Paula, M. I. et al. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis\u2014A cohort single-center study. Transpl. Int. 34, 339\u2013352. https:\/\/doi.org\/10.1111\/tri.13800 (2021).","journal-title":"Transpl. Int."},{"key":"16847_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.12659\/aot.895677","volume":"21","author":"H Kamei","year":"2016","unstructured":"Kamei, H. et al. Cytomegalovirus (CMV) monitoring after liver transplantation: Comparison of CMV Pp65 antigenemia assay with real-time PCR calibrated to WHO international standard. Ann. Transplant. 21, 131\u2013136. https:\/\/doi.org\/10.12659\/aot.895677 (2016).","journal-title":"Ann. Transplant."},{"key":"16847_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2174\/187152611797636703","volume":"11","author":"SA Ross","year":"2011","unstructured":"Ross, S. A., Novak, Z., Pati, S. & Boppana, S. B. Overview of the diagnosis of cytomegalovirus infection. Infect. Disord. Drug Targets 11, 466\u2013474. https:\/\/doi.org\/10.2174\/187152611797636703 (2011).","journal-title":"Infect. Disord. Drug Targets"},{"key":"16847_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.bjid.2016.08.007","volume":"20","author":"C Henrique Pinto","year":"2016","unstructured":"Henrique Pinto, C. et al. Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation. Braz. J. Infect. Dis. 20, 576\u2013584. https:\/\/doi.org\/10.1016\/j.bjid.2016.08.007 (2016).","journal-title":"Braz. J. Infect. Dis."},{"key":"16847_CR32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","volume":"102","author":"C Roufosse","year":"2018","unstructured":"Roufosse, C. et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 102, 1795\u20131814. https:\/\/doi.org\/10.1097\/TP.0000000000002366 (2018).","journal-title":"Transplantation"},{"key":"16847_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006 (2009).","journal-title":"Ann. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16847-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:53:27Z","timestamp":1669352007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16847-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16847"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16847-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12783"}}